XFOR
X4 Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.04
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 15.8M | 35.1M | 2.6M | — | — |
| Cost of Revenue | 3.0M | 6.3M | 797.0K | — | — |
| Gross Profit | 12.9M | 28.9M | 1.8M | — | — |
| Operating Expenses | |||||
| R&D Expense | 66.3M | 72.2M | 81.6M | 72.0M | 61.1M |
| SG&A Expense | 34.4M | 43.5M | 61.5M | 35.5M | 27.0M |
| General & Admin Expense | 15.5M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (105.0M) | — | (509.0K) |
| Total Operating Expenses | 100.8M | 115.7M | 38.2M | 107.5M | 87.6M |
| Cost and Expenses | 103.8M | 122.0M | 39.0M | 107.5M | 87.6M |
| Operating Income (EBIT) | (87.9M) | (86.9M) | (36.4M) | (107.5M) | (87.6M) |
| Non-Operating | |||||
| Interest Income | 7.0M | 4.6M | 5.8M | 4.6M | 219.0K |
| Interest Expense | 8.7M | 8.9M | 8.8M | 5.8M | 4.0M |
| Net Interest Income | (1.8M) | (4.3M) | (3.0M) | (1.2M) | (3.8M) |
| Other Non-Op Income/Expense | (2.3M) | 7.7M | (739.0K) | 6.4M | (6.3M) |
| Non-Operating Income (excl Interest) | (6.5M) | (16.6M) | (8.0M) | (12.2M) | 2.3M |
| EBT (Pre-Tax Income) | (90.2M) | (79.2M) | (37.1M) | (101.1M) | (93.8M) |
| Income Tax Expense | (28.0K) | 41.0K | 310.0K | 78.0K | 28.0K |
| Bottom Line | |||||
| Net Income | (90.1M) | (79.2M) | (37.5M) | (101.2M) | (93.9M) |
| Earnings from Cont. Ops | (90.1M) | (79.2M) | (37.5M) | (101.2M) | (93.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (90.1M) | (79.2M) | (37.5M) | (101.2M) | (96.4M) |
| Per Share | |||||
| Basic EPS | ($1.20) | ($1.87) | ($5.59) | ($17.07) | ($45.60) |
| Diluted EPS | ($1.20) | ($1.87) | ($5.59) | ($17.07) | ($45.60) |
| Revenue Per Share | $0.13 | $0.83 | $0.38 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 126.3M | 42.3M | 6.7M | 5.9M | 2.1M |
| Diluted Shares Outstanding | 126.3M | 42.3M | 6.7M | 5.9M | 2.1M |
| Profitability Metrics | |||||
| EBITDA | (79.5M) | (69.0M) | (27.6M) | (94.9M) | (89.3M) |
| D&A | 1.9M | 1.3M | 796.0K | 419.0K | 513.0K |
| EBIT | (81.4M) | (70.3M) | (28.4M) | (95.3M) | (89.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026